Resverlogix Corp.
1.200.02 (1.69%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close1.18
Bid1.17 x
Ask1.23 x
52wk Range1.00 - 2.52
Day's Range1.17 - 1.20
Avg Vol (3m)16,877
As of 3:24 PM EDT. Market closed.
  • Zacks Small Cap Research25 days ago

    RVX: Initiating with CAD$5.00 Target: Successful BETonMACE Provides Material Upside

    Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production.  Novel compounds arising from Resverlogix's epigenetic drug development platform function by inhibiting Bromodomain and Extra Terminal domain (BET) proteins and have the potential to impact multiple biologies and diseases.  Resverlogix is engaged in the development of novel therapies for important global medical markets in a variety of broad areas of cardiovascular disease (CVD), atherosclerosis, neurodegenerative diseases, renal conditions and potentially other orphan indications. Apabetalone (RVX-208) has a multifactorial approach and impacts several key biological processes that play a role in vascular disease risk. Apabetalone is the first selective BET bromodomain inhibitor in clinical trials for high-risk vascular disease.  Resverlogix is the first to test apabetalone in the reduction of major adverse cardiac events (MACE) in diabetic and chronic kidney disease (CKD) patients, and has a seven-year head start in the arena of epigenetic small molecules for CVD risk reduction.  Analysis of prior Phase 2 clinical trials data (“ASSERT,” “ASSURE,” and “SUSTAIN”) indicated that apabetalone significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who also have a low level of high-density lipoprotein (HDL) and elevated C-reactive protein (CRP), and other select populations with unmet medical need.

  • Zacks Small Cap Research6 months ago

    RVX: Moving Along with Phase 3 BETonMACE; Re-iterating ‘Buy’ Rating & Increasing Price Target

    Resverlogix Corp. (RVX.TO) (RVXCF) began recruiting and dosing participants in the Phase 3 BETonMACE trial of apabetalone (RVX-208) in high-risk CVD patients with diabetes in November 2015. Dosing commenced two weeks after the opening of the first clinical trial sites.